Lrrc75b is a novel negative regulator of C2C12 myogenic differentiation

5Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Many transcription factors and signaling molecules involved in the guidance of myogenic differentiation have been investigated in previous studies. However, the precise molecular mechanisms of myogenic differentiation remain largely unknown. In the present study, by performing a meta-analysis of C2C12 myogenic differentiation microarray data, we found that leucine-rich repeat-containing 75B (Lrrc75b), also known as AI646023, a molecule of unknown biological function, was downregulated during C2C12 myogenic differentiation. The knockdown of Lrrc75b using specific siRNA in C2C12 myoblasts markedly enhanced the expression of muscle-specifi c myogenin and increased myoblast fusion and the myotube diameter. By contrast, the adenovirus-mediated overexpression of Lrrc75b in C2C12 cells markedly inhibited myoblast differentiation accompanied by a decrease in myogenin expression. In addition, the phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2) was suppressed in the cells in which Lrrc75b was silenced. Taken together, our results demonstrate that Lrrc75b is a novel suppressor of C2C12 myogenic differentiation by modulating myogenin and Erk1/2 signaling.

Cite

CITATION STYLE

APA

Zhong, Y., Zou, L., Wang, Z., Pan, Y., Dai, Z., Liu, X., … Zuo, C. (2016). Lrrc75b is a novel negative regulator of C2C12 myogenic differentiation. International Journal of Molecular Medicine, 38(5), 1411–1418. https://doi.org/10.3892/ijmm.2016.2738

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free